Company Profile

Microbot Medical Inc (AKA: StemCells Inc~Cellular Transplants~Cytotherapeutics Inc~CytoTherapeutics Inc)
Profile last edited on: 3/5/2019      CAGE: 507G3      UEI: EJ27HMVA7VM9

Business Identifier: Stem cell-based, CNS-focused therapeutics
Year Founded
1988
First Award
1990
Latest Award
2010
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

25 Recreation Park Drive Unit 108
Hingham, MA 02043
   (781) 875-3605
   info@microbotmedical.com
   www.microbotmedical.com
Location: Multiple
Congr. District: 08
County: Plymouth

Public Profile

Having been renamed several times, until 2016 the firm was dba as StemCells (NASDAQ:STEM). In Novermber 2016 - in some trouble, the firm did a reverse merger with privately held, Israeli firm MicroBot Medical and now trades under that name (NASDAQ:MBOT). Where the orginal StemCells had been organized around cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development: stem cell therapies and encapsulated cell therapies. With a total personnel restructure, the new entity dba Microbot Medical and is a medical device company specializing in the design and development of transformational micro-robotic medical technologies, primarily focused on leveraging its micro-robotic technologies with the goal of allowing more physicians to treat more patients while improving surgical outcomes for patients. With its HQ and faciliites in Hingham, MA the firm's first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and TipCAT, a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : MBIO
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $403,885
Project Title: Towards The Creation Of Hcv-Resistant Liver Cells For Transplantation
2005 2 NIH $464,276
Project Title: CNS Stem Cells for Alzheimer's Disease Therapy
2003 1 NIH $342,493
Project Title: Testing of human CNS-SC in a spinal cord injury model
2002 2 NIH $600,000
Project Title: Liver Stem Cells And Humanized Mice: A New Model For HCV
2000 1 NIH $198,614
Project Title: Testing Of Normal Human Cns-Nsc In A Parkinson's Model

Key People / Management

  Ian Massey -- President and Chief Operating Officer

  Martin McGlynn -- CEO

  Alexandra Capela

  George A Carlson

  Lisa Christenson

  Orion D Hegre

  William F Hickey

  Stephen Huhn -- Vice President, Clinical Research and Chief Medical Officer

  Jakop Jacobs

  Eric Lagasse

  Michael J Lysaght

  Joel Naor -- Vice President, Clinical Development, Ophthalmology

  Ann Tsukamoto -- Executive Vice President, Scientific and Strategic Alliances

  Nobuko Uchida -- Vice President, Stem Cell Biology